Rapid and efficient reprogramming of human fetal and adult blood CD34 + cells into mesenchymal stem cells with a single factor

Cell Research

Volumn 23, Issue 5, 2013, Pages 658-672

  Meng, Xianmei ^a   Su, Rui Jun ^a   Baylink, David J ^a   Neises, Amanda ^a   Kiroyan, Jason B ^a   Lee, Wayne Yuk Wai ^b   Payne, Kimberly J ^a   Gridley, Daila S ^a   Wang, Jun ^a   Lau, K H William ^c   Li, Gang ^b   Zhang, Xiao Bing ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Jerry L Pettis Memorial VA Medical Center   (United States)

Author keywords

CD34 + cells; direct reprogramming; hematopoietic cells; mesenchymal stem cells

Indexed keywords

CD34 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; OCTAMER TRANSCRIPTION FACTOR 4;

ANIMAL; ARTICLE; BLOOD CELL; BONE; CELL CULTURE; CELL DIFFERENTIATION; CONNECTIVE TISSUE; CYTOLOGY; DRUG ANTAGONISM; FETUS BLOOD; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPING; LENTIVIRINAE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; NUCLEAR REPROGRAMMING; PATHOLOGY;

ANIMALS; ANTIGENS, CD34; BLOOD CELLS; BONE AND BONES; CELL DIFFERENTIATION; CELLS, CULTURED; CONNECTIVE TISSUE; FETAL BLOOD; GENETIC VECTORS; GLYCOGEN SYNTHASE KINASE 3; HEMATOPOIETIC STEM CELLS; HUMANS; KARYOTYPING; LENTIVIRUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; TRANSDUCTION, GENETIC;

LENTIVIRUS; MUS;

EID: 84877151170     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2013.40     Document Type: Article

References (45)

1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
2. Chamberlain JR, Schwarze U, Wang PR, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004; 303:1198-1201.
3. Uematsu K, Hattori K, Ishimoto Y, et al. Cartilage regeneration using mesenchymal stem cells and a three-dimensional poly-lactic-glycolic acid (PLGA) scaffold. Biomaterials 2005; 26:4273-4279.
4. Young RG, Butler DL, Weber W, Caplan AI, Gordon SL, Fink DJ. Use of mesenchymal stem cells in a collagen matrix for achilles tendon repair. J Orthop Res 1998; 16:406-413.
5. Fan H, Liu H, Wong EJW, Toh SL, Goh JCH. In vivo study of anterior cruciate ligament regeneration using mesenchymal stem cells and silk scaffold. Biomaterials 2008; 29:3324-3337.
6. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet; 371:1579-1586.
7. Dalal J, Gandy K, Domen J. Role of mesenchymal stem cell therapy in Crohn's disease. Pediatr Res 2012; 71:445-451.
8. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
9. Domínguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C. Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med 2011; 1:59-63.
10. Mosna F, Sensebe L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev 2010; 19:1449-1470.
11. Lian Q, Zhang Y, Zhang J, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010; 121:1113-1123.
12. Deyle DR, Khan IF, Ren G, et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther 2012; 20:204-213.
13. Jung Y, Bauer G, Nolta JA. Concise review: induced pluri-potent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells 2012; 30:42-47.
14. Ring KL, Tong LM, Balestra ME, et al. Direct reprogram-ming of mouse and human fbroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012; 11:100-109.
15. Han DW, Tapia N, Hermann A, et al. Direct reprogramming of fbroblasts into neural stem cells by defned factors. Cell Stem Cell 2012; 10:465-472.
16. Song K, Nam YJ, Luo X, et al. Heart repair by reprogram-ming non-myocytes with cardiac transcription factors. Nature 2012; 485:599-604.
17. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogram-ming of fbroblasts into functional cardiomyocytes by defned factors. Cell 2010; 142:375-386.
18. Huang P, He Z, Ji S, et al. Induction of functional hepatocyte-like cells from mouse fbroblasts by defned factors. Nature 2011; 475:386-389.
19. Sekiya S, Suzuki A. Direct conversion of mouse fbroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475:390-393.
20. Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009; 5:434-441.
21. Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 2009; 5:353-357.
22. Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009; 114:5473-5480.
23. Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood 2009; 113:5476-5479.
24. Giorgetti A, Marchetto MC, Li M, et al. Cord blood-derived neuronal cells by ectopic expression of Sox2 and c-Myc. Proc Natl Acad Sci USA 2012; 109:12556-12561.
25. Meng X, Neises A, Su RJ, et al. Effcient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther 2012; 20:408-416.
26. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22:625-634.
27. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005; 121:465-477.
28. Chou BK, Mali P, Huang X, et al. Effcient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 2011; 21:518-529.
29. Sun YQ, Deng MX, He J, et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway in-fammation in mice. Stem Cells 2012; 30:2692-2699.
30. Fu QL, Chow YY, Sun SJ, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy 2012; 67:1215-1222.
31. Domev H, Amit M, Laevsky I, Dar A, Itskovitz-Eldor J. Ef-fcient engineering of vascularized ectopic bone from human embryonic stem cell-derived mesenchymal stem cells. Tissue Eng Part A 2012; 18:2290-302.
32. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor OCT4. Cell 1998; 95:379-391.
33. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122:947-956.
34. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by de-fned factors. Cell 2006; 126:663-676.
35. Lengner CJ, Welstead GG, Jaenisch R. The pluripotency regulator OCT4: a role in somatic stem cells? Cell Cycle 2008; 7:725-728.
36. Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kogler G. OCT4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007; 1:364-366.
37. Lengner CJ, Camargo FD, Hochedlinger K, et al. OCT4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 2007; 1:403-415.
38. Greco SJ, Liu K, Rameshwar P. Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. Stem Cells 2007; 25:3143-3154.
39. Tsai CC, Su PF, Huang YF, Yew TL, Hung SC. OCT4 and nanog directly regulate dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. Mol Cell 2012; 47:169-182.
40. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifes cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63:2244-2250.
41. Cantz T, Key G, Bleidissel M, et al. Absence of OCT4 expression in somatic tumor cell lines. Stem Cells 2008; 26:692-697.
42. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fbroblasts are down-regulated with passaging. Stem Cells Dev 2011; 20:53-66.
43. Bae S, Ahn J, Park C, et al. Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fbroblasts. Cell Tissue Res 2009; 335:565-573.
44. Meng X, Baylink DJ, Sheng M, et al. Erythroid promoter confnes FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation. PLoS One 2012; 7:e37569.
45. Zhang XB, Beard BC, Beebe K, Storer B, Humphries RK, Kiem HP. Differential effects of HOXB4 on nonhuman primate short-and long-term repopulating cells. PLoS Med 2006; 3:e173.